The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma

• DOI: 10.1097/fpc.0b013e32834e3572
• Publication Date: 2011-12-01T17:53:57Z
• Authors: Nina Erčulj; Viljem Kovač; Julija Hmeljak; Alenka Franko; Metoda Dodič-Fikfak; Vita Dolžan
• Keywords: Adult; Aged, 80 and over; Male; Mesothelioma; Genotype; Middle Aged; Deoxycytidine; Polymorphism, Single Nucleotide; Biomarkers, Pharmacological; Disease-Free Survival; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Haplotypes; Cytidine Deaminase; Deoxycytidine Kinase; Humans; Female; Promoter Regions, Genetic; Genetic Association Studies; Aged; Neoplasm Staging; Retrospective Studies

Identification of biomarkers that could predict gemcitabine efficacy and toxicity is a key issue in the development of individualized therapy. The aim of our study was to evaluate the influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma (MM).In total, 107 patients with MM, treated with gemcitabine-platinum chemotherapy, were genotyped for 11 polymorphisms in deoxycytidine kinase, ribonucleotide reductase M1 (RRM1), and cytidine deaminase genes using KASPar assays. Binary logistic regression was used to evaluate the influence of selected polymorphisms on tumor response and occurrence of treatment-related toxicity, while their influence on survival was estimated by Cox proportional hazards model. A haplotype analysis was carried out to assess the combined effect of RRM1 polymorphisms.Deoxycytidine kinase and cytidine deaminase polymorphisms did not influence treatment outcome in patients with MM. In multivariable analysis, RRM1 2927A>C polymorphism significantly decreased overall survival probability [hazard ratio (HR)=2.02; 95% confidence interval (CI)=1.11-3.65; P=0.021]. Two promoter polymorphisms, RRM1 -524T>C and -37C>A, decreased the odds of nausea/vomiting grade≥2 occurrence [odds ratio (OR)=0.25; 95% CI=0.10-0.60; P=0.002 and OR=0.26; 95% CI=0.11-0.63; P=0.003, respectively]. RRM1 TTCCA haplotype was associated with worse tumor response (OR=16.67; 95% CI=2.38-100.00; P=0.004) and worse overall survival (HR=2.97; 95% CI=1.46-6.06; P=0.003) compared with the most frequent TTCAA haplotype, while TCACA haplotype influenced nausea/vomiting grade≥2 occurrence (OR=0.27; 95% CI=0.12-0.60; P=0.001).RRM1 polymorphisms as well as haplotypes showed an association with gemcitabine treatment efficacy and toxicity; therefore, they should be validated as potential markers for the prediction of clinical outcome in patients with MM.